ATE425251T1 - Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen - Google Patents

Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen

Info

Publication number
ATE425251T1
ATE425251T1 AT99914725T AT99914725T ATE425251T1 AT E425251 T1 ATE425251 T1 AT E425251T1 AT 99914725 T AT99914725 T AT 99914725T AT 99914725 T AT99914725 T AT 99914725T AT E425251 T1 ATE425251 T1 AT E425251T1
Authority
AT
Austria
Prior art keywords
mimic
carbohydrates
vaccines containing
streptococcus group
antidiotypic
Prior art date
Application number
AT99914725T
Other languages
German (de)
English (en)
Inventor
Giuseppe Teti
Luciano Polonelli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE425251T1 publication Critical patent/ATE425251T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4233—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-bacterial Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99914725T 1998-04-20 1999-04-20 Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen ATE425251T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9808327.2A GB9808327D0 (en) 1998-04-20 1998-04-20 Antidiotypic compounds

Publications (1)

Publication Number Publication Date
ATE425251T1 true ATE425251T1 (de) 2009-03-15

Family

ID=10830608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99914725T ATE425251T1 (de) 1998-04-20 1999-04-20 Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen

Country Status (9)

Country Link
US (2) US6676938B1 (enExample)
EP (1) EP1071763B1 (enExample)
JP (2) JP4446601B2 (enExample)
AT (1) ATE425251T1 (enExample)
CA (1) CA2325566C (enExample)
CY (1) CY1109140T1 (enExample)
DE (1) DE69940545D1 (enExample)
GB (1) GB9808327D0 (enExample)
WO (1) WO1999054457A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027695A1 (de) * 1999-05-27 2001-04-19 Max Delbrueck Centrum Vakzine gegen konformationsabhängige Antigene sowie gegen Antigene, die keine oder nicht ausschließlich Proteine oder Peptide sind
ES2330083T3 (es) * 2000-10-27 2009-12-04 Novartis Vaccines And Diagnostics S.R.L. Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
AU2003260102A1 (en) * 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
CA2575548A1 (en) 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
US20090104218A1 (en) * 2004-12-22 2009-04-23 J. Craig Venter Institute Group B Streptococcus
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
PT2054431E (pt) * 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
WO2008108830A2 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
JP5653215B2 (ja) 2007-09-12 2015-01-14 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
EP2537857B1 (en) * 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
EP3773348B1 (en) 2018-04-10 2025-04-02 Alps Holding Llc Spinal interbody cage comprising top and bottom faces with mesh structures, pillars and slots

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
WO1997045449A1 (en) * 1996-05-29 1997-12-04 Derek Nigel John Hart Dendritic cell receptor
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
US6444787B1 (en) * 1997-12-31 2002-09-03 Research Development Institute, Inc. Method of isolating a peptide which immunologically mimics microbial carbohydrates including group B streptococcal carbohydrates and the use thereof in a vaccine

Also Published As

Publication number Publication date
EP1071763B1 (en) 2009-03-11
CY1109140T1 (el) 2014-07-02
GB9808327D0 (en) 1998-06-17
JP2002512026A (ja) 2002-04-23
CA2325566C (en) 2011-02-08
EP1071763A1 (en) 2001-01-31
DE69940545D1 (de) 2009-04-23
JP2009179645A (ja) 2009-08-13
WO1999054457A1 (en) 1999-10-28
US20040101536A1 (en) 2004-05-27
US6900302B2 (en) 2005-05-31
US6676938B1 (en) 2004-01-13
JP4446601B2 (ja) 2010-04-07
CA2325566A1 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
ATE425251T1 (de) Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen
DK0673255T3 (da) Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
YU48509B (sh) Suspenzije u kondenzovanim potisnim gasovima
DK234789A (da) Antistoffer mod latente human papillomavirusproteiner, diagnostiske systemer og diagnostiske metoder
NO971875D0 (no) Cathepsin 02 protease
BR9407377A (pt) Toxina hibrida
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
IT8819187A0 (it) Sistema di bilanciamento mediante pistone a vapore in trazione, particolarmente per turbomotori agas.
DE69636453D1 (de) Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp)
ATE444360T1 (de) T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
HUP9902457A2 (hu) Pneumococcus felületi fehérjéket tartalmazó oltóanyag-készítmények
NO910656L (no) Sperrevaeske-tetningsanordning for turbokompressor.
ATE197506T1 (de) Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
WO1998039450A3 (de) Oberflächenprotein (spsa-protein) von streptococcus pneumoniae deletierte abkömmlinge, expressionssssystem für diese proteine und vaccine mit den proteinen
DE68917556D1 (de) Quinolyloxazol-2-one, nützlich als Proteinkinase-C-Inhibitoren.
DE3382718D1 (de) Peptide, die eine Immunogen-Lage des Poliovirus des Sabin-Stammes enthalten.
NO910655D0 (no) Sperrevaeske-tetningsanordning for turbokompressor.
EP0955366A4 (en) ANTIGENIC PROTEIN FROM MALASSEZIA
FI911973A0 (fi) Traodaktigt hemagglutinin av b. pertussis-bacill.
ATE120209T1 (de) Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.
MY131433A (en) Novel metazoan parasite antigens having pepstatin binding activity and their use in vaccines
FI854839A0 (fi) Vaccin eller diagnostisk produkt erhaollen fraon peptid, samt daeri anvaendbar polypeptid.
ATE132502T1 (de) Peptide, die epitope auf r-ifn-beta repräsentieren, antikörper dagegen, und ihre anwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1071763

Country of ref document: EP